In a previous trial of aminometramid on 30 patients with peripheral edema, 19 became refractory to the drug. These 19 patients and another group of 16 with peripheral edema or ascites were placed on another nonmercurial diuretic aminoisometradine, which had shown promise in previous studies in animals and man. This group of 35 patients who had previously required frequent injections of mercurial diuretics were treated with the new diuretic for at least 8 months. Conclusions of this study are presented.
IN A previous report,' dealing with the clinical evaluation of aminometramid (Mictine) in a group of 30 patients with peripheral edema due to congestive heart failure, 19 patients who had responded well at the outset developed resistance to the action of the drug after 5 to 20 weeks of therapy. These 19 patients were then given another nonmercurial diuretic drug, a derivative of pyrimidinedione, known as aminoisometradine (Rolicton).* The initial response of this group of 19 patients to the new drug appeared promising and another study was organized to include these patients plus a new group of patients with congestive heart failure. Five patients with ascites and edema caused by Laennee's cirrhosis were also added to the study.
Impetus was given to our efforts to find a satisfactory nonmercurial diuretic by the presence of over 150 patients weekly at the diuretic injection clinic at this hospital. Prob A few additional patients entered and left the study during this time but are not included because of insufficient observation. The criteria used in determining diuretic requirements were signs of weight gain, peripheral edema, pulmonary congestion, hepatic enlargement, and subjective symptoms of dyspnea and orthopnea. These also served as standards in evaluating success or failure of therapy. The age, diagnosis, and other pertinent data are given in table 1 .
Each patient had a 6-foot roentgen film of the chest and a 12-lead electrocardiogram. In addition, levels of serum sodium, potassium, chlorides, and blood urea nitrogen were determined. These were used as a baseline in determining the biochemical effects of the diuretic agent under study. The examinations listed above were repeated periodically and the patients were observed initially and at last biweekly thereafter. At each visit special attention was paid to weight gain or loss and to the existence of peripheral edema. Heart and lungs were examined routinely and any dyspnea, orthopnea, or symptoms of toxicity were noted.
They were then given Rolicton, which was obtainable only at each clinic visit. The dosage varied from 400 mg. to 5 Gm. daily and was changed as the patient's clinical condition reqci-ed. Repeated biochemical studies revealed no significant changes from the baseline levels established at the start of the study and there were no symptoms of toxicity reported. The drug was uniformly well tolerated. It was found that if a total daily dose of 2 Gm. was insufficient to control fluid retention, little was gained by further increase in dose. Doses as high as 5 Gm. daily were well tolerated.
Inasmuch as patients with severe congestive failure requiring frequent mercurial injections were not benefited to any degree, it appears premature to conclude that a satisfactory nonmercurial oral diuretic has been obtained. The problem of fluid retention is still with us and continued search for an oral diuretic effective in advanced failure is warranted.
The optimum dose varied with each patient. It was found that 800 mg. to 1.6 Gm., 2 to 4 tablets in divided doses daily, were usually satisfactory. There was no special need to take the drug with meals. 
